CTOs on the Move

BlackThorn Therapeutics

www.blackthornrx.com

 
BlackThorn Therapeutics is a neurobehavioral health company developing targeted therapeutics, informed by a deep understanding of brain and behavior relationships, to significantly improve patient outcomes.
  • Number of Employees: 25-100
  • Annual Revenue: $0-1 Million

Executives

Name Title Contact Details

Funding

BlackThorn Therapeutics raised $76M on 06/13/2019

Similar Companies

Pharm Agra Labs

Pharm Agra Labs is a Brevard, NC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Cepheid

Based in Sunnyvale, Calif., Cepheid is a leading molecular diagnostics company that is dedicated to improving healthcare by developing, manufacturing, and marketing accurate yet easy-to-use molecular systems and tests. By automating highly complex and time-consuming manual procedures, the company`s solutions deliver a better way for institutions of any size to perform sophisticated genetic testing for organisms and genetic-based diseases. Through its strong molecular biology capabilities, the company is focusing on those applications where accurate, rapid, and actionable test results are needed most, such as managing infectious diseases and cancer.

Planetrx Com

Planetrx Com is a South San Francisco, CA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Genesis Bioventures

Genesis Bioventures, Inc. is a Surrey, BC-based company in the Healthcare, Pharmaceuticals, and Biotech sector.

Synlogic

Synlogic is a clinical-stage biotechnology company developing medicines through its proprietary approach to synthetic biology. Synlogic`s pipeline includes its lead program in phenylketonuria (PKU), which has demonstrated proof of concept with plans to start a pivotal, Phase 3 study in the second half of 2022, and additional novel drug candidates designed to treat homocystinuria (HCU) and enteric hyperoxaluria. The rapid advancement of these potential biotherapeutics, called Synthetic Biotics, has been enabled by Synlogic`s proprietary, reproducible, target-specific drug design. Synlogic uses programmable, precision genetic engineering of well-characterized probiotics to exert localized activity for therapeutic benefit, with a focus on metabolic and immunologic diseases. Synlogic is also working with Roche in a research collaboration focused on the discovery of a novel Synthetic Biotic for the treatment of inflammatory bowel disease and with Ginkgo Bioworks to include additional undisclosed preclinical assets, combining Synlogic`s approach to Synthetic Biotics with Ginkgo`s Codebase and Foundry services.